Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed to investigate the mechan...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiong, Zhewen, Chan, Stephen Lam, Zhou, Jingying, Vong, Joaquim S. L., Kwong, Tsz Tung, Zeng, Xuezhen, Wu, Haoran, Cao, Jianquan, Tu, Yalin, Feng, Yu, Yang, Weiqin, Wong, Patrick Pak-Chun, Si-Tou, Willis Wai-Yiu, Liu, Xiaoyu, Wang, Jing, Tang, Wenshu, Liang, Zhixian, Lu, Jiahuan, Li, Ka Man, Low, Jie-Ting, Chan, Michael Wing-Yan, Leung, Howard H. W., Chan, Anthony W. H., To, Ka-Fai, Yip, Kevin Yuk-Lap, Lo, Yuk Ming Dennis, Sung, Joseph Jao Yiu, Cheng, Alfred Sze-Lok
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2023
Subjects:
Science::Medicine
Cancer Immunobiology
Hepatocellular Carcinoma
Online Access:https://hdl.handle.net/10356/170964
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed to investigate the mechanisms underlying tumour adaptation to immune-checkpoint targeting.

Similar Items